Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. [electronic resource]
Producer: 20200505Description: 23 p. digitalISSN:- 1742-6405
- Adenine -- analogs & derivatives
- Adult
- Aged
- Alanine
- Anti-HIV Agents -- therapeutic use
- Antiretroviral Therapy, Highly Active
- Cobicistat -- therapeutic use
- Darunavir -- therapeutic use
- Drug Combinations
- Drug Substitution
- Emtricitabine -- therapeutic use
- Female
- HIV Infections -- drug therapy
- HIV-1 -- drug effects
- Humans
- Male
- Middle Aged
- Protease Inhibitors -- therapeutic use
- Sustained Virologic Response
- Tablets
- Tenofovir -- therapeutic use
- Viral Load -- drug effects
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.